Pattern recognition receptors-Molecular orchestrators of inflammation in inflammatory bowel disease

Cytokine and Growth Factor Reviews

Volumn 24, Issue 2, 2013, Pages 91-104

  Walsh, David ^a   McCarthy, Joanna ^a   O'Driscoll, Caitriona ^a   Melgar, Silvia ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cancer; Inflammatory bowel disease; NLR; Pattern recognition receptors; TLR

Indexed keywords

C TYPE LECTIN RECEPTOR; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CD209 ANTIGEN; CYCLOOXYGENASE 2; DECTIN 1; DOUBLE STRANDED RNA; INFLAMMASOME; MAJOR HISTOCOMPATIBILITY COMPLEX TRANSACTIVATOR CLASS II; MANNOSE BINDING LECTIN; MEMBRANE PROTEIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN 12; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN 14; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN 3; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN 4; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN 5; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN 6; PATTERN RECOGNITION RECEPTOR; PROTEIN LGP 2; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

CELL PROLIFERATION; COLITIS ASSOCIATED CANCER; CROHN DISEASE; DIMERIZATION; ENTERITIS; ENZYME ACTIVATION; HUMAN; IMMUNE EVASION; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MISSENSE MUTATION; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; SHORT SURVEY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; RECEPTORS, PATTERN RECOGNITION;

EID: 84875269936     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.09.003     Document Type: Short Survey

References (156)

1. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunological Reviews 2009, 227(1):221-233.
2. Meylan E., Tschopp J., Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006, 442(7098):39-44. 10.1038/nature04946.
3. Henckaerts L., Pierik M., Joossens M., Ferrante M., Rutgeerts P., Vermeire S. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007, 56(November (11)):1536-1542.
4. Karin M., Lawrence T., Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124(4):823-835.
5. Fukata M., Chen A., Vamadevan A.S., Cohen J., Breglio K., Krishnareddy S., et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133(December (6)):1869-1881.
6. Fukata M., Abreu M.T. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008, 27(2):234-243.
7. Melgar S., Shanahan F. Inflammatory bowel disease-from mechanisms to treatment strategies. Autoimmunity 2010, 43(7):463-477.
8. Shanahan F., Bernstein C.N. The evolving epidemiology of inflammatory bowel disease. Current Opinion in Gastroenterology 2009, 25(4):301-305.
9. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448(7152):427-434. 10.1038/nature06005.
10. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annual Review of Immunology 2010, 28(1):573-621.
11. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140(6). 1807-16.e1.
12. Peterson D.A., Frank D.N., Pace N.R., Gordon J.I. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host & Microbe 2008, 3(6):417-427.
13. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunology 2010, 11(May (5)):373-384.
14. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nature Reviews: Cancer 2009, 9(1):57-63. 10.1038/nrc2541.
15. Abraham C., Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011, 140(6):1729-1737.
16. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflammatory Bowel Diseases 2010, 16(9):1583-1597.
17. Abreu M.T., Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. The Journal of Pediatrics 2004, 144(4):421-429.
18. Cantó E., Ricart E., Monfort D., González-Juan D., Balanzó J., Rodríguez-Sánchez J.L., et al. TNFα production to TLR2 ligands in active IBD patients. Clinical Immunology 2006, 119(2):156-165.
19. Szebeni B., Veres G., Dezsõfi A., Rusai K., Vannay á., Mraz M., et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clinical & Experimental Immunology 2008, 151(1):34-41.
20. Hausmann M., Kiessling S., Mestermann S., Webb G., Spöttl T., Andus T., et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002, 122(7):1987-2000.
21. Heimesaat M.M., Fischer A., Siegmund B., Kupz A., Niebergall J., Fuchs D., et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via toll-like receptors 2 and 4. PLoS ONE 2007, 2(7):e662.
22. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 2004, 118(2):229-241.
23. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007, 132(4):1359-1374.
24. Pierik M., Joossens S., Van Steen K., Van Schuerbeek N., Vlietinck R., Rutgeerts P., et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflammatory Bowel Diseases 2006, 12(1):1-8.
25. Tahara T., Arisawa T., Wang F., Shibata T., Nakamura M., Sakata M., et al. Toll-like receptor 2-196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Science 2007, 98(11):1790-1794.
26. Hornef M.W., Normark B.H., Vandewalle A., Normark S. Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. The Journal of Experimental Medicine 2003, 198(8):1225.
27. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. The Journal of Experimental Medicine 2003, 197(4):403.
28. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infection and Immunity 2000, 68(12):7010.
29. Ferguson L.R., Shelling A.N., Browning B.L., Huebner C., Petermann I. Genes, diet and inflammatory bowel disease. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2007, 622(1-2):70-83.
30. Cho J.H., Nicolae D.L., Gold L.H., Fields C.T., LaBuda M.C., Rohal P.M., et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proceedings of the National Academy of Sciences 1998, 95(13):7502.
31. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nature Genetics 2000, 25(2):187-191.
32. Elson C.O., Cong Y., McCracken V.J., Dimmitt R.A., Lorenz R.G., Weaver C.T. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunological Reviews 2005, 206(1):260-276.
33. Papadimitraki E.D., Bertsias G.K., Boumpas D.T. Toll like receptors and autoimmunity: a critical appraisal. Journal of Autoimmunity 2007, 29(4):310-318.
34. Hold G.L., Rabkin C.S., Chow W.H., Smith M.G., Gammon M.D., Risch H.A., et al. A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007, 132(3):905-912.
35. Otto F., Schmid P., Mackensen A., Wehr U., Seiz A., Braun M., et al. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. European Journal of Cancer 1996, 32(10):1712-1718.
36. Cario E. Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword. Inflammatory Bowel Diseases 2008, 14(3):411-421.
37. Huang B., Zhao J., Li H., He K.L., Chen Y., Mayer L., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Research 2005, 65(12):5009.
38. Fort M.M., Mozaffarian A., Stöver A.G., Correia J.S., Johnson D.A., Crane R.T., et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. The Journal of Immunology 2005, 174(10):6416.
39. Ungaro R., Fukata M., Hsu D., Hernandez Y., Breglio K., Chen A., et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. American Journal of Physiology: Gastrointestinal and Liver Physiology 2009, 296(June (6)):G1167-G1179.
40. O'Neill L.A.J., Bryant C.E., Doyle S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacological Reviews 2009, 61(2):177.
41. Vijay-Kumar M., Wu H., Aitken J., Kolachala V.L., Neish A.S., Sitaraman S.V., et al. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflammatory Bowel Diseases 2007, 13(7):856-864.
42. Sitaraman S.V., Klapproth J.M., Moore D.A., Landers C., Targan S., Williams I.R., et al. Elevated flagellin-specific immunoglobulins in Crohn's disease. American Journal of Physiology: Gastrointestinal and Liver Physiology 2005, 288(2):G403-G406.
43. Vijay-Kumar M., Sanders C.J., Taylor R.T., Kumar A., Aitken J.D., Sitaraman S.V., et al. Deletion of TLR5 results in spontaneous colitis in mice. The Journal of Clinical Investigation 2007, 117(12):3909-3921.
44. Rhee S.H., Im E., Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008, 135(2). 518-28.e3.
45. Paul-Clark M.J., George P.M., Gatheral T., Parzych K., Wright W.R., Crawford D., et al. Pharmacology and therapeutic potential of pattern recognition receptors. Pharmacology & Therapeutics 2012, 135(2):200-215.
46. Török H.-P., Glas J., Tonenchi L., Bruennler G., Folwaczny M., Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004, 127(1):365-366.
47. Rachmilewitz D., Karmeli F., Takabayashi K., Hayashi T., Leider-Trejo L., Lee J., et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002, 122(May (5)):1428-1441.
48. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126(February (2)):520-528.
49. Katakura K., Lee J., Rachmilewitz D., Li G., Eckmann L., Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. The Journal of Clinical Investigation 2005, 115(3):695-702.
50. Lee H.K., Brown S.J., Rosen H., Tobias P.S. Application of beta-lactamase enzyme complementation to the high-throughput screening of toll-like receptor signaling inhibitors. Molecular Pharmacology 2007, 72(October (4)):868-875.
51. Salcedo R., Worschech A., Cardone M., Jones Y., Gyulai Z., Dai R.-M., et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. The Journal of Experimental Medicine 2010, 207(August (8)):1625-1636.
52. Pull S.L., Doherty J.M., Mills J.C., Gordon J.I., Stappenbeck T.S. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(January (1)):99-104.
53. Rosenstiel P., Till A., Schreiber S. NOD-like receptors and human diseases. Microbes and Infection 2007, 9(5):648-657.
54. Shaw P.J., McDermott M.F., Kanneganti T.-D. Inflammasomes and autoimmunity. Trends in Molecular Medicine 2011, 17(2):57-64.
55. Franchi L., Eigenbrod T., Munoz-Planillo R., Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nature Immunology 2009, 10(3):241-247. 10.1038/ni.1703.
56. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Molecular Cell 2002, 10(2):417-426.
57. Lamkanfi M. Emerging inflammasome effector mechanisms. Nature Reviews: Immunology 2011, 11(3):213-220. 10.1038/nri2936.
58. Tattoli I., Travassos L., Carneiro L., Magalhaes J., Girardin S. The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Seminars in Immunopathology 2007, 29(3):289-301.
59. Franchi L., Warner N., Viani K., Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. Immunological Reviews 2009, 227(1):106-128.
60. Rivas M.A., Beaudoin M., Gardet A., Stevens C., Sharma Y., Zhang C.K., et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nature Genetics 2011, 43(11):1066-1073. 10.1038/ng.952.
61. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005, 54(August (8)):1182-1193.
62. Brain O., Allan P., Simmons A. NOD2-mediated autophagy and Crohn disease. Autophagy 2010, 6(3):412-414.
63. Maeda S., Hsu L.-C., Liu H., Bankston L.A., Iimura M., Kagnoff M.F., et al. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 2005, 307(February (5710)):734-738.
64. Lakatos P.L., Lakatos L., Szalay F., Willheim-Polli C., Osterreicher C., Tulassay Z., et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World Journal of Gastroenterology 2005, 11(10):1489-1495.
65. Franke A., Ruether A., Wedemeyer N., Karlsen T.H., Nebel A., Schreiber S. No association between the functional CARD4 insertion/deletion polymorphism and inflammatory bowel diseases in the German population. Gut 2006, 55(November (11)):1679-1680.
66. Lu W.G., Zou Y.F., Feng X.L., Yuan F.L., Gu Y.L., Li X., et al. Association of NOD1 (CARD4) insertion/deletion polymorphism with susceptibility to IBD: a meta-analysis. World Journal of Gastroenterology 2010, 16(September (34)):4348-4356.
67. Chen G.Y., Shaw M.H., Redondo G., Núñez G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Research 2008, 68(December (24)):10060-10067.
68. Strober W., Murray P.J., Kitani A., Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nature Reviews: Immunology 2006, 6(1):9-20. 10.1038/nri1747.
69. Geddes K., Magalhaes J.G., Girardin S.E. Unleashing the therapeutic potential of NOD-like receptors. Nature Reviews: Drug Discovery 2009, 8(6):465-479. 10.1038/nrd2783.
70. Natividad J.M.M., Petit V., Huang X., de Palma G., Jury J., Sanz Y., et al. Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-/-;Nod2-/- mice. Inflammatory Bowel Diseases 2012, 18(8):1434-1446.
71. Netea M.G., Ferwerda G., de Jong D.J., Werts C., Boneca I.G., Jéhanno M., et al. The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists. Journal of Biological Chemistry 2005, 280(October (43)):35859-35867.
72. Sutterwala F.S., Mijares L.A., Li L., Ogura Y., Kazmierczak B.I., Flavell R.A. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. The Journal of Experimental Medicine 2007, 204(December (13)):3235-3245.
73. Miao E.A., Mao D.P., Yudkovsky N., Bonneau R., Lorang C.G., Warren S.E., et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proceedings of the National Academy of Sciences 2010, 107(February (7)):3076-3080.
74. Broz P., Newton K., Lamkanfi M., Mariathasan S., Dixit V.M., Monack D.M. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. The Journal of Experimental Medicine 2010, 207(August (8)):1745-1755.
75. Sutterwala F.S., Flavell R.A. NLRC4/IPAF: a CARD carrying member of the NLR family. Clinical Immunology 2009, 130(1):2-6.
76. Franchi L., Kamada N., Nakamura Y., Burberry A., Kuffa P., Suzuki S., et al. NLRC4-driven production of IL-1[beta] discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nature Immunology 2012, 13(5):449-456. 10.1038/ni.2263.
77. Hu B., Elinav E., Flavell R.A. Inflammasome-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. Cell Cycle 2011, 10(12):1936-1939.
78. Hu B., Elinav E., Huber S., Booth C.J., Strowig T., Jin C., et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proceedings of the National Academy of Sciences 2010, 107(December (50)):21635-21640.
79. Braddock M., Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nature Reviews: Drug Discovery 2004, 3(4):330-340. 10.1038/nrd1342.
80. Carter J.D., Valeriano J., Vasey F.B. Crohn disease worsened by Anakinra administration. JCR: Journal of Clinical Rheumatology 2003, 9(4):276-277.
81. Benko S., Magalhaes J.G., Philpott D.J., Girardin S.E. NLRC5 limits the activation of inflammatory pathways. The Journal of Immunology 2010, 185(August (3)):1681-1691.
82. Kuenzel S., Till A., Winkler M., Häsler R., Lipinski S., Jung S., et al. The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. The Journal of Immunology 2010, 184(February (4)):1990-2000.
83. Yao Y., Wang Y., Chen F., Huang Y., Zhu S., Leng Q., et al. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens. Cell Research 2012, 22(5):836-847.
84. Meissner T.B., Li A., Biswas A., Lee K.-H., Liu Y.-J., Bayir E., et al. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proceedings of the National Academy of Sciences 2010, 107(August (31)):13794-13799.
85. Kumar H., Pandey S., Zou J., Kumagai Y., Takahashi K., Akira S., et al. NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections. The Journal of Immunology 2011, 186(January (2)):994-1000.
86. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.-D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32(3):379-391.
87. Dowds T.A., Masumoto J., Zhu L., Inohara N., Núñez G. Cryopyrin-induced interleukin 1β secretion in monocytic cells. Journal of Biological Chemistry 2004, 279(May (21)):21924-21928.
88. Villani A.-C., Lemire M., Fortin G., Louis E., Silverberg M.S., Collette C., et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nature Genetics 2009, 41(1):71-76. 10.1038/ng.285.
89. Creagh E.M., O Neill L.A.J. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends in Immunology 2006, 27(8):352-357.
90. Allen I.C., TeKippe E.M., Woodford R.-M.T., Uronis J.M., Holl E.K., Rogers A.B., et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. The Journal of Experimental Medicine 2010, 207(May (5)):1045-1056.
91. Bauer C., Duewell P., Mayer C., Lehr H.A., Fitzgerald K.A., Dauer M., et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010, 59(September (9)):1192-1199.
92. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe?. Immunity 2010, 32(3):300-302.
93. Mitroulis I., Skendros P., Ritis K. Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome. European Journal of Internal Medicine 2010, 21(3):157-163.
94. Stutz A., Golenbock D.T., Latz E. Inflammasomes: too big to miss. Journal of Clinical Investigation 2009, 119(December (12)):3502-3511.
95. Grenier J.M., Wang L., Manji G.A., Huang W.-J., Al-Garawi A., Kelly R., et al. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-κB and caspase-1. FEBS Letters 2002, 530(1-3):73-78.
96. Chen G.Y., Liu M., Wang F., Bertin J., Núñez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. The Journal of Immunology 2011, 186(June (12)):7187-7194.
97. Elinav E., Strowig T., Kau Andrew L., Henao-Mejia J., Thaiss Christoph A., Booth Carmen J., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145(5):745-757.
98. Werts C., le Bourhis L., Liu J., Magalhaes J.G., Carneiro L.A., Fritz J.H., et al. Nod1 and Nod2 induce CCL5/RANTES through the NF-κB pathway. European Journal of Immunology 2007, 37(9):2499-2508.
99. Williams K.L., Lich J.D., Duncan J.A., Reed W., Rallabhandi P., Moore C., et al. The CATERPILLER protein Monarch-1 is an antagonist of Toll-like receptor-, tumor necrosis factor α-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. Journal of Biological Chemistry 2005, 280(December (48)):39914-39924.
100. Lich J.D., Williams K.L., Moore C.B., Arthur J.C., Davis B.K., Taxman D.J., et al. Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. Journal of Immunology 2007, 178(February (3)):1256-1260.
101. Zaki M.H., Vogel P., Malireddi R.K.S., Body-Malapel M., Anand Paras K., Bertin J., et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011, 20(5):649-660.
102. Kim T.W., Park H.J., Choi E.Y., Jung K.C. Overexpression of CIITA in T cells aggravates Th2-mediated colitis in mice. Journal of Korean Medical Science 2006, 21(5):877-882.
103. Netea M.G., Azam T., Ferwerda G., Girardin S.E., Kim S.H., Dinarello C.A. Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. Journal of Leukocyte Biology 2006, 80(December (6)):1454-1461.
104. Garrity-Park M.M., Loftus E.V., Sandborn W.J., Bryant S.C., Smyrk T.C. MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut 2009, 58(September (9)):1226-1233.
105. Friese M.A., Jones E.Y., Fugger L. MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends in Immunology 2005, 26(11):559-561.
106. Yoneyama M., Fujita T. Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity 2008, 29(2):178-181.
107. Hirata Y., Broquet A.H., Menchén L., Kagnoff M.F. Activation of innate immune defense mechanisms by signaling through RIG-I/IPS-1 in intestinal epithelial cells. The Journal of Immunology 2007, 179(October (8)):5425-5432.
108. Schlee M., Roth A., Hornung V., Hagmann C.A., Wimmenauer V., Barchet W., et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31(July (1)):25-34.
109. Schmidt A., Schwerd T., Hamm W., Hellmuth J.C., Cui S., Wenzel M., et al. 5'-Triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(July (29)):12067-12072.
110. Rehwinkel J., Tan C.P., Goubau D., Schulz O., Pichlmair A., Bier K., et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010, 140(3):397-408.
111. Poeck H., Ruland J. From virus to inflammation: mechanisms of RIG-I-induced IL-1beta production. European Journal of Cell Biology 2012, 91(January (1)):59-64.
112. Poeck H., Bscheider M., Gross O., Finger K., Roth S., Rebsamen M., et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1[beta] production. Nature Immunology 2010, 11(1):63-69. 10.1038/ni.1824.
113. Saito T., Hirai R., Loo Y., Owen D., Johnson C., Sinha S., et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(2):582-587.
114. Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. Journal of Immunology 2005, 175(5):2851-2858.
115. Rothenfusser S., Goutagny N., DiPerna G., Gong M., Monks B.G., Schoenemeyer A., et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. The Journal of Immunology 2005, 175(October (8)):5260-5268.
116. Funke B., Lasitschka F., Roth W., Penzel R., Meuer S., Saile M., et al. Selective downregulation of retinoic acid-inducible gene I within the intestinal epithelial compartment in Crohn's disease. Inflammatory Bowel Diseases 2011, 17(9):1943-1954.
117. Kutikhin A.G., Yuzhalin A.E. C-type lectin receptors and RIG-I-like receptors: new points on the oncogenomics map. Cancer Manage Res 2012, 4:39-53.
118. Wang Y., Zhang H.-X., Sun Y.-P., Liu Z.-X., Liu X.-S., Wang L., et al. Rig-I-/- mice develop colitis associated with downregulation of G[alpha]i2. Cell Research 2007, 17(10):858-868.
119. Öhman L., Franzén L., Rudolph U., Birnbaumer L., Hörnquist E.H. Regression of Peyer's patches in Gαi2 deficient mice prior to colitis is associated with reduced expression of Bcl-2 and increased apoptosis. Gut 2002, 51(September (3)):392-397.
120. Hampe J., Lynch N.J., Daniels S., Bridger S., Macpherson A.J.S., Stokkers P., et al. Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut 2001, 48(February (2)):191-197.
121. Morosky S.A., Zhu J., Mukherjee A., Sarkar S.N., Coyne C.B. Retinoic acid-induced gene-I (RIG-I) associates with nucleotide-binding oligomerization domain-2 (NOD2) to negatively regulate inflammatory signaling. Journal of Biological Chemistry 2011, 286(August (32)):28574-28583.
122. Hirabayashi K., Yano J., Inoue T., Yamaguchi T., Tanigawara K., Smyth G.E., et al. Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Research 1999, 59(September (17)):4325-4333.
123. Cheng Y.S., Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biology and Therapy 2011, 10(January (12)):1219-1223.
124. Yu M., Levine S.J. Toll-like receptor 3, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. Cytokine & Growth Factor Reviews 2011, 22(2):63-72.
125. Robinson M.J., Sancho D., Slack E.C., LeibundGut-Landmann S., Sousa CRe. Myeloid C-type lectins in innate immunity. Nature Immunology 2006, 7(12):1258-1265. 10.1038/ni1417.
126. Geijtenbeek T.B.H., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nature Reviews: Immunology 2009, 9(7):465-479. 10.1038/nri2569.
127. Sivaram G., Tiwari S.K., Bardia A., Manoj G., Santhosh B., Saikant R., et al. Association of genetic variants of mannan-binding (MBL) lectin-2 gene, MBL levels and function in ulcerative colitis and Crohn's disease. Innate Immunity 2011, 17(December (6)):526-531.
128. Turner M.W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunology Today 1996, 17(11):532-540.
129. Turner M.W. The role of mannose-binding lectin in health and disease. Molecular Immunology 2003, 40(7):423-429.
130. Summerfield J.A., Ryder S., Sumiya M., Thursz M., Gorchein A., Monteil M.A., et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults. The Lancet 1995, 345(8954):886-889.
131. Seppänen M., Lokki M.-L., Lappalainen M., Hiltunen-Back E., Rovio A.T., Kares S., et al. Mannose-binding lectin 2 gene polymorphism in recurrent herpes simplex virus 2 infection. Human Immunology 2009, 70(4):218-221.
132. Rector A., Lemey P., Laffut W., Keyaerts E., Struyf F., Wollants E., et al. Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn's disease. Genes and Immunity 2001, 2(6):323-328.
133. Wang F.Y., Arisawa T., Tahara T., Nagasaka M., Fujita H., Hirata I., et al. The role of mannan-binding lectin (MBL) gene polymorphism in ulcerative colitis. Journal of Clinical Biochemistry and Nutrition 2008, 42:54-58.
134. Müller S., Schaffer T., Flogerzi B., Seibold-Schmid B., Schnider J., Takahashi K., et al. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut 2010, 59(November (11)):1493-1500.
135. van Kooyk Y., Geijtenbeek T.B. DC-SIGN: escape mechanism for pathogens. Nature Reviews: Immunology 2003, 3(September (9)):697-709.
136. Geijtenbeek T.B.H., van Vliet S.J., Koppel E.A., Sanchez-Hernandez M., Vandenbroucke-Grauls C.M.J.E., Appelmelk B., et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. The Journal of Experimental Medicine 2003, 197(January (1)):7-17.
137. Gringhuis S.I., den Dunnen J., Litjens M., van het Hof B., van Kooyk Y., Geijtenbeek Teunis B.H. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-κB. Immunity 2007, 26(5):605-616.
138. Velde AAt, van Kooyk Y., Braat H., Hommes D.W., Dellemijn T.A.M., Slors J.F.M., et al. Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn's disease. European Journal of Immunology 2003, 33(1):143-145.
139. Rioux J.D., Silverberg M.S., Daly M.J., Steinhart A.H., McLeod R.S., Griffiths A.M., et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. The American Journal of Human Genetics 2000, 66(6):1863-1870.
140. Nagaoka K., Takahara K., Tanaka K., Yoshida H., Steinman R.M., Saitoh S., et al. Association of SIGNR1 with TLR4-MD-2 enhances signal transduction by recognition of LPS in gram-negative bacteria. International Immunology 2005, 17(July (7)):827-836.
141. Saunders S.P., Barlow J.L., Walsh C.M., Bellsoi A., Smith P., McKenzie A.N.J., et al. C-Type lectin SIGN-R1 has a role in experimental colitis and responsiveness to lipopolysaccharide. The Journal of Immunology 2010, 184(March (5)):2627-2637.
142. Van Gisbergen K.P.J.M., Aarnoudse C.A., Meijer G.A., Geijtenbeek T.B.H., van Kooyk Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Research 2005, 65(July (13)):5935-5944.
143. Nonaka M., Ma B.Y., Imaeda H., Kawabe K., Kawasaki N., Hodohara K., et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. Journal of Biological Chemistry 2011, 286(June (25)):22403-22413.
144. Brown G.D. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nature Reviews: Immunology 2006, 6(1):33-43. 10.1038/nri1745.
145. Underhill D.M., Rossnagle E., Lowell C.A., Simmons R.M. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood 2005, 106(October (7)):2543-2550.
146. De Vries H.S., Plantinga T.S., van Krieken J.H., Stienstra R., van Bodegraven A.A., Festen E.A.M., et al. Genetic association analysis of the functional c.714T>G polymorphism and mucosal expression of Dectin-1 in inflammatory bowel disease. PLoS ONE 2009, 4(11):e7818.
147. Heinsbroek S., Oei A., Roelofs J., Dhawan S., te Velde A., Gordon S., et al. Genetic deletion of dectin-1 does not affect the course of murine experimental colitis. BMC Gastroenterology 2012, 12(1):33.
148. Iliev I.D., Funari V.A., Taylor K.D., Nguyen Q., Reyes C.N., Strom S.P., et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 2012, 336(June (6086)):1314-1317.
149. Foxman E.F., Iwasaki A. Genome-virome interactions: examining the role of common viral infections in complex disease. Nature Reviews: Microbiology 2011, 9(April (4)):254-264.
150. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140(6):821-832.
151. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004, 53(7):987.
152. Morré S.A., Murillo L.S., Spaargaren J., Fennema H.S.A., Peña A.S. Role of the toll-like receptor 4 Asp299Gly polymorphism in susceptibility to Candida albicans infection. Journal of Infectious Diseases 2002, 186(9):1377.
153. Travassos L.H., Carneiro L.A.M., Ramjeet M., Hussey S., Kim Y.-G., Magalhaes J.G., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nature Immunology 2010, 11(1):55-62. 10.1038/ni.1823.
154. Kim Y.-G., Kamada N., Shaw Michael H., Warner N., Chen Grace Y., Franchi L., et al. The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity 2011, 34(5):769-780.
155. Cummings J.R.F., Cooney R.M., Clarke G., Beckly J., Geremia A., Pathan S., et al. The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens 2010, 76(1):48-56.
156. Onoguchi K., Yoneyama M., Fujita T., Miyashita M., Oshiumi H., Matsumoto M., et al. Intracellular receptors for viral and bacterial infections. International Immunology Meeting Abstracts 2010, 22(August (Suppl. 1 Pt 3)):iii73-iii75.